Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2

Dengfeng Li; Lei Chen; Zhen Hu; Hua Li; Jia Li; Chuankui Wei; Yixiang Huang; Hongming Song; Lin Fang
July 2014
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 7, p4008
Academic Journal
No abstract available.


Related Articles

  • Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Bhat-Nakshatri, Poornima; Wang, Guohua; Collins, Nikail R.; Thomson, Michael J.; Geistlinger, Tim R.; Carroll, Jason S.; Brown, Myles; Hammond, Scott; Srour, Edward F.; Liu, Yunlong; Nakshatri, Harikrishna // Nucleic Acids Research;2009, Vol. 37 Issue 14, p4850 

    Estradiol (E2) regulates gene expression at the transcriptional level by functioning as a ligand for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). E2-inducible proteins c-Myc and E2Fs are required for optimal ERα activity and secondary estrogen responses, respectively....

  • MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2Δ16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance. Huynh, Felicia C.; Jones, Frank E. // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    The oncogenic isoform of HER2, HER2Δ16, is expressed with HER2 in nearly 50% of HER2 positive breast tumors where HER2Δ16 drives metastasis and resistance to multiple therapeutic interventions including tamoxifen and trastuzumab. In recent years microRNAs have been shown to influence...

  • MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Lu, Lin; Ju, Fang; Zhao, Hui; Ma, Xuezhen // Biotechnology Letters;Dec2015, Vol. 37 Issue 12, p2387 

    Objectives: To investigate the role of microRNAs in doxorubicin resistance of breast cancer cells. Results: MicroRNA-134 was down-regulated in doxorubicin-resistant and doxorubicin-sensitive breast cancer samples and MCF-7/ADR cell lines. After transfection of miR-134 mimics, an MTT assay...

  • Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Planas-Silva, Maricarmen; Hamilton, Kecia // Cancer Chemotherapy & Pharmacology;Oct2007, Vol. 60 Issue 4, p535 

    Many studies have implicated the non-receptor tyrosine kinase c-Src in the development and metastatic progression of many types of cancer. In breast cancer, c-Src has been proposed to mediate the actions of estrogen in cell cycle progression. In this study we investigated the interaction between...

  • Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer. Devlin, Kaylyn L.; Sanford, Tiffany; Harrison, Lauren M.; LeBourgeois, Paul; Lashinger, Laura M.; Mambo, Elizabeth; Hursting, Stephen D. // PLoS ONE;7/19/2016, Vol. 11 Issue 7, p1 

    MicroRNAs have emerged as ubiquitous post-transcriptional regulators that coordinate many fundamental processes within cells, including those commonly linked to cancer when dysregulated. Profiling microRNAs across stages of cancer progression provides focus as to which microRNAs are key players...

  • Insulin-Like Growth Factor-1 Signaling Regulates miRNA Expression in MCF-7 Breast Cancer Cell Line. Martin, Elizabeth C.; Bratton, Melyssa R.; Yun Zhu; Rhodes, Lyndsay V.; Tilghman, Syreeta L.; Collins-Burow, Bridgette M.; Burow, Matthew E. // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    In breast carcinomas, increased levels of insulin-like growth factor 1 (IGF-1) can act as a mitogen to augment tumorigenesis through the regulation of MAPK and AKT signaling pathways. Signaling through these two pathways allows IGF-1 to employ mechanisms that favor proliferation and cellular...

  • Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA). Hannafon, Bethany N.; Carpenter, Karla J.; Berry, William L.; Janknecht, Ralf; Dooley, William C.; Wei-Qun Ding // Molecular Cancer;2015, Vol. 14 Issue 1, p1 

    Background: Docosahexaenoic acid (DHA) is a natural compound with anticancer and anti-angiogenesis activity that is currently under investigation as both a preventative agent and an adjuvant to breast cancer therapy. However, the precise mechanisms of DHA's anticancer activities are unclear. It...

  • Identification of microprocessor-dependent cancer cells allows screening for growth-sustaining micro-RNAs. Peric, D; Chvalova, K; Rousselet, G // Oncogene;4/19/2012, Vol. 31 Issue 16, p2039 

    Micro-RNAs are deregulated in cancer cells, and some are either tumor suppressive or oncogenic. In addition, a link has been established between decreased expression of micro-RNAs and transformation, and several proteins of the RNA interference pathway have been shown to be haploinsufficient...

  • The clinical potential of microRNAs. Budhu, Anuradha; Junfang Ji; Wang, Xin W. // Journal of Hematology & Oncology;2010, Vol. 3, p37 

    MicroRNAs are small noncoding RNAs that function to control gene expression. These small RNAs have been shown to contribute to the control of cell growth, differentiation and apoptosis, important features related to cancer development and progression. In fact, recent studies have shown the...

  • MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Boll, K; Reiche, K; Kasack, K; Mörbt, N; Kretzschmar, A K; Tomm, J M; Verhaegh, G; Schalken, J; von Bergen, M; Horn, F; Hackermüller, J // Oncogene;1/17/2013, Vol. 32 Issue 3, p277 

    With ∼30 000 deaths annually in the United States, prostate cancer (PCa) is a major oncologic disease. Here we show that the microRNAs miR-130a, miR-203 and miR-205 jointly interfere with the two major oncogenic pathways in prostate carcinoma and are downregulated in cancer tissue. Using...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics